Sheriedan Grannan
Family · Cheyenne, WYNPI 1417326075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $784, 2.6 times the $301 reported in 2021. Among family clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$484
- Lilly USA, LLC$238
- Supernus Pharmaceuticals, Inc.$223
- Novo Nordisk$195
- AbbVie$187
- Corium, LLC$162
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,58499%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $484 |
| Lilly USA, LLC | 13 | $238 |
| Supernus Pharmaceuticals, Inc. | 10 | $223 |
| Novo Nordisk | 11 | $195 |
| AbbVie | 8 | $187 |
| Corium, LLC | 9 | $162 |
| Lundbeck LLC | 7 | $143 |
| Amgen | 8 | $124 |
| Pfizer | 5 | $113 |
| Abbott | 3 | $65 |
| Alfasigma USA, Inc. | 4 | $63 |
| Exact Sciences | 4 | $62 |
| Viiv Healthcare Company | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| GSK | 2 | $38 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Boehringer Ingelheim | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Digestive Care, Inc. | 1 | $28 |
| Vertex | 1 | $26 |
| Corcept Therapeutics | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$2,605 in reported general payments places this provider in the 90th percentile of 284 family providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 33 | $40,064 |
| TrulicityDulaglutide | 31 | $34,369 |
| RexultiBrexpiprazole | 13 | $18,740 |
| EliquisApixaban | 13 | $13,586 |
| RybelsusSemaglutide | 12 | $11,701 |
| JanuviaSitagliptin Phosphate | 12 | $10,421 |
| OxycontinOxycodone Hcl | 13 | $9,572 |
| BelsomraSuvorexant | 15 | $6,401 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $6,069 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,043 |
| Metaxalone | 12 | $3,387 |
| Methylphenidate ErMethylphenidate Hcl | 19 | $3,221 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 60 | $1,637 |
| Hydroxyzine Hcl | 27 | $1,336 |
| Gabapentin | 71 | $1,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $238 | $74,43364 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $48 | $18,74013 claims |
| PfizerEliquis | $113 | $13,58613 claims |
| Novo NordiskRybelsus | $195 | $11,70112 claims |
| Boehringer IngelheimGlyxambi | $28 | $6,06912 claims |
| GSKIncruse Ellipta | $38 | $4,04311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 284 family providers in Wyoming.
Other family in Cheyenne
- Jill GiranyCheyenne$44K
- Kathryn HeimerCheyenne$5K
- Greta SkagenCheyenne$4K
- Jennifer DavisCheyenne$4K
- Anne BarnesCheyenne$4K
- Katherine BrockCheyenne$3K
- Lana SykesCheyenne$3K
- Shala SwarmCheyenne$2K
- Heather RobertsCheyenne$2K
- Kristi RoybalCheyenne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.